Home / Learn / Immunotherapy / Novel Therapies

Novel Therapies

Members of the ACCC IO Institute Executive Committee discuss the potential benefits big data could play in helping providers determine who should be tested for immunotherapy and why It’s essential for community practices to understand how to use biomarkers to stratify patients and select appropriate patients for IO clinical trials. (features Lee Schwartzberg, MD, FACP; Jennie Crews, MD, MMM, FACP; and Ivo Abraham PhD, RN)


The Latest Resources

  • CAR T-Cell Therapy: A Post-ASH Update
    Ran Reshef, MD, MSc

    Ran Ranshef, MD, MSc, spoke to the ACCC Immuno-Oncology Institute about advancements in chimeric antigen receptor (CAR) T-cell therapy presented at the 2018 American Society of Hematology (ASH) Annual Meeting.

  • Virtual Navigation to Clinical Trials
    By Jennifer C. King, PhD

    In the current oncology clinical trials landscape, many barriers remain to clinical trial enrollment that affect both the oncologist and the patient. Among these are trial locations, strict eligibility requirements, insufficient resources to support appropriate clinical trial education and screening, as well as patient and provider attitudes about trials.

  • [Publication] Immuno-Oncology: Connecting Science, Policy, and Real-World Care Delivery

    This publication from the ACCC Immuno-Oncology Institute (IO Institute) highlights 2018-2019 accomplishments, provides a cancer immunotherapy clinical update (as of November 2018), and explores current and ongoing education and resource development guided by the IO Institute's Working Groups.
  • The IO Journey Continues
    Lee Schwartzberg, MD, FACP
    Lee Schwartzberg, MD, FACP, Chair, ACCC IO Institute Executive Committee, shares his perspective on immuno-oncology (IO) highlights from 2018 and what next steps in the IO journey may be in 2019.

From Oncology Issues

  • A Physician Champion Takes a Practice-Based Immunotherapy Program to the Next Level
    Tracy Virgilio, RN, MSN, OCN
    Early symptom management is key to improving quality of life for patients with cancer, and proactive monitoring delivers unparalleled survival advantage while decreasing emergency visits and admissions. However, immunotherapies require special attention and procedures. Sidney Kimmel Cancer Center earned a 2018 ACCC Innovator Award for their immunotherapy triage algorithms, which provide non-oncology physicians and nurses with the tools to manage IO patients and prevent unnecessary admissions.
  • Immuno-Oncology: Breaking Barriers, Exploring Solutions, Improving Patient Care
    The ACCC Immuno-Oncology Institute developed a multidisciplinary curriculum workshop bringing together faculty experienced in delivery of immunotherapy with cancer program staff in the earlier stages of IO integration. Over the past two years, these IO Visiting Experts Programs were hosted by ACCC Cancer Program Members nation-wide.
  •  Best Practices for Implementing Cancer Immunotherapy in the Community
    The Association of Community Cancer Centers (ACCC) recently hosted live continuing medical education (CME)-certified learning workshops at two community cancer programs to review current barriers to immunotherapy implementation in the community setting. During the workshops, an expert faculty panel engaged participants in discussion on the challenges that they may face as they integrate immunotherapy into their clinical practice, as well as practical solutions and strategies they can apply to overcome these barriers. This article summarizes the guidance and information provided by the faculty on the various issues raised during the workshop discussions.
  •  Highlights from ASCO 2018
    By Cary A. Presant, MD, FACP, FASCO
    ASCO 2018 offered a wealth of new data that will continue to transform clinical practice and cancer program development. Most important, implementation of the scientifi c advances we learned at ASCO 2018 will improve the length and quality of life of our cancer patients.
  •  Turning on the Light Switch
    By Ann McGreal, RN
    Discover how 2017 ACCC Innovator Award winner Advocate Medical Group developed and implemented an immunotherapy program, lessons learned, and tools created to educate staff and patients.
  •  Best of ASCO 2017
    Cary A. Presant, MD, FACP, FASCO
    ASCO 2017 was filled with new information and long lines as 39,000 oncologists worldwide came together to hear the latest advances in cancer care.
  •  Real-World Experiences in Immunotherapy Delivery
    The ACCC education project, “Real-World Experiences in Immunotherapy Delivery,” addresses some of the practical issues that cancer programs must navigate to provide immunotherapy safely and effectively in their own communities.
  •  Advancing Immuno-Oncology in the Community Setting
    Steven Powell, MD
    As cancer treatment evolves with the emergence of genomics, personalized therapies, and immunotherapies, care delivery must also transform.

Blog Posts